Corresponds to the adjusted odds ratio.
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We identified 30,355 patients with HS; their characteristics are described in Table I (Table II) .
Patients with HS who were not receiving IS had a very low incidence of HZ. Exposure to IS was associated with a tripling of the crude incidence of HZ, although the incidence was still less than 2%. The likelihood of development of HZ among patients with HS, compared to patients without HS, was similar regardless of exposure to IS, suggesting that IS use does not modify the relationship between HS and HZ. The incidence of HZ among patients with HS appears to approximate the rates observed in the general US population. In a claims-based analysis, the overall incidence rate of HZ among adults was observed to be 4.47 per 1000 person-years. 4 We could not account for HZ vaccination in this analysis. Because of the low number of events in each group, we could not stratify risk of HZ by type of IS.
We conclude that risk of development of HZ infection among patients with HS is only slightly higher than among patients without HS. The risk however is still low, even with exposure to IS. Although the need for vaccination should be assessed for patients individually, those with HS generally may not require HZ vaccination, even with immunomodulation, before the age of 50 years. Disclosure: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, and Asana Biosciences and has received honoraria.
The sponsor has had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Reprints not available from the authors. 1 This lymphoma has been called the oncologist's great imitator for its myriad presentations. 2 There are 2 subtypes: Western (classic), with predominantly cutaneous and central nervous system manifestations, and Asian, which presents as fulminant multiorgan failure. 3 The cutaneous presentation varies from purpura to irregular telangiectasias, tender erythematous patches and plaques, and vasculitis. This lymphoma is typically widely disseminated, 3 and presenting symptoms can be vague and highly variable. Diagnosis is often made postmortem. IVBCL is highly aggressive; with treatment, patients have an overall survival of ;30%. 
